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ease, left ventricular dysfunction, and other comorbid conditions.Differential survival after coronary revascularization proce-
These results suggest that management decisions among pa-dures among patients with renal insufficiency.
tients with coronary artery disease should be made in the con-Background. Acute myocardial infarction, cardiac arrest,
text of not only location and severity of coronary artery lesions,and other cardiac events are the major cause of mortality
but also on the presence and severity of renal dysfunction.among patients with renal insufficiency. Previous studies of
interventions for coronary artery disease among patients with
renal insufficiency have not controlled for potentially con-
founding factors such as coronary artery disease severity and
The mortality rate for patients with end-stage renalleft ventricular function. This study investigates the compara-
disease (ESRD) during their first year of dialysis istive survival for patients with renal insufficiency and coronary
artery disease following coronary artery bypass graft (CABG) greater than 20%, with more than one half of deaths
surgery as compared with percutaneous coronary artery inter- related to cardiac disease [1]. Furthermore, ESRD pa-
vention (PCI), while controlling for confounding factors. tients who survive myocardial infarction have an almost
Methods. This retrospective cohort study of patients under-
60% mortality rate during the year following this eventgoing CABG surgery or PCI discharged between 1993 and
[2]. At initiation of dialysis, one quarter of dialysis patients1995 uses the New York Department of Health databases and
Cox proportional hazards analyses to estimate the mortality have atherosclerotic coronary artery disease (CAD), and
risk associated with CABG as compared with PCI for patients almost 10% have had a prior myocardial infarction [1].
with renal insufficiency. Renal function was categorized as cre- As recognized by the U.S. Renal Data System [1] and
atinine2.5 mg/dL (N 58,329), creatinine2.5 mg/dL (N
the National Kidney Foundation’s Task Force to Study840), and end-stage renal disease (ESRD) requiring dialysis
Cardiovascular Disease Among Patients with Chronic(N  407).
Results. Patients with either ESRD or serum creatinine2.5 Renal Failure [3], this exaggerated burden of cardiovas-
mg/dL had more severe coronary artery disease and a greater cular disease begins well before the onset of ESRD, that
frequency of comorbid conditions as compared with patients is, during the period of early renal insufficiency [4].
with creatinine2.5 mg/dL. Creatinine2.5 mg/dL and ESRD
The primary intervention strategies available at presentwere both associated with an increased mortality risk among
for CAD include coronary artery bypass graft (CABG)all distributions of coronary artery disease anatomy. Among
patients with ESRD, the risk ratio (RR) of mortality for pa- surgery and percutaneous coronary artery intervention
tients undergoing CABG compared with PCI was 0.39 (95% (PCI). In clinical trials comparing these procedures among
CI, 0.22 to 0.67, P  0.0006). Among patients with creatinine patients with normal kidney function, CABG surgery is
2.5 mg/dL, CABG surgery did not convey a survival benefit
associated with an improved quality of life [5] and withover PCI (RR, 0.86, 95% CI, 0.56 to 1.33, P  0.50).
fewer subsequent diagnostic and therapeutic interven-Conclusions. This study demonstrates a survival benefit among
patients with ESRD undergoing CABG surgery as compared tions [6–8]. While no long-term survival differences were
with PCI, while controlling for severity of coronary artery dis- demonstrated between PCI and CABG surgery among
patients overall [8–11], subgroup analyses have revealed
that patients with diabetes mellitus [9], impaired left
Key words: chronic renal insufficiency, percutaneous coronary artery
ventricular function [12, 13], or greater severity of CADangioplasty, CABG surgery, end-stage renal disease, cardiovascular
disease, left ventricular dysfunction, acute myocardial infarction. [11, 14] experience a survival benefit from CABG surgery.
Multiple studies have compared these treatmentsReceived for publication October 5, 2000
among patients with ESRD [15–21]. A recent analysisand in revised form January 3, 2001
Accepted for publication January 25, 2001 suggested that ESRD patients undergoing CABG sur-
gery had better survival and fewer subsequent myocar- 2001 by the International Society of Nephrology
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dial infarctions, as compared with ESRD patients under- allograft are placed in the group of ESRD requiring
dialysis.going PCI [risk ratio (RR)  0.91, P  0.002, and RR 
The New York State Vital Statistics Death File for the0.37, P  0.0001, respectively] [21]. Because data on left
years 1993 through 1996 was used to determine whetherventricular function and severity of CAD were unavail-
patients who were discharged from the hospital aliveable for inclusion in this sentinel analysis, all conclusions
reached the primary endpoint of all-cause death duringmust be interpreted with the recognition that these fac-
the remainder of the study period following their initialtors influence survival and are generally more severe
revascularization. If death occurred before December 31,among patients who undergo CABG surgery [16, 18, 20].
1996, the time from the procedure until death was noted.Among patients with chronic renal insufficiency not on
For patients who had not expired before December 31,dialysis, the presence of renal insufficiency is an indepen-
1996, the time from the procedure until December 31,dent risk factor for poorer survival [22, 23]. No study,
1996, was recorded. The death file identifies all residentshowever, has compared PCI to CABG surgery among
of New York State who die each year and can be linkedthis population to determine their comparative survival
to the clinical registries using the patient’s social securitybenefits. This study was therefore undertaken to investi-
number. Procedure-related mortalities were included ingate the comparative survival following CABG surgery
the analysis.and PCI for patients with chronic renal insufficiency and
for patients with ESRD while controlling for severity of Descriptive analysis
CAD, left ventricular dysfunction, and other comorbid
Demographic and clinical factors were compared be-conditions.
tween cohorts of patients stratified on renal function and
type of coronary revascularization procedure (PCI vs.
METHODS CABG surgery). For a comparison of CABG surgery and
PCI, patients with left main disease and those presentingDescription of data set
with an acute myocardial infarction within 24 hours ofThis study included 59,576 New York State residents
a revascularization procedure were excluded becausewho underwent isolated CABG surgery (CABG surgery
these clinical features dominate the choice of revasculari-with no other major open heart procedures during the
zation strategy [11]. Binomial proportions were calcu-same admission) or PCI as an initial intervention for
lated for categorical variables and compared between
CAD between January 1, 1993, and December 31, 1995.
cohorts using the chi-square test.
Two New York State registries, the Cardiac Surgery Re-
porting System (CSRS) and the Coronary Angioplasty Survival analysis
Reporting System (CARS), were the sources of the data Given the differences in severity of CAD between
for the study. These previously described data sets con- cohorts of patients categorized by renal function, patient
tain patient-specific demographics; selected laboratory survival was modeled separately in each of the eight
measures; information on cardiac catheterization and cor- CAD anatomic groups using Cox proportional hazards
onary artery revascularization procedures; admission, sur- regression [25] to assess the independent effect of renal
gery, and discharge dates; and discharge status [11, 24]. failure (either creatinine2.5 mg/dL or ESRD) on mor-
These registries also contain information on the presence tality risk. For these and subsequent analyses, stepwise
and anatomic distribution of coronary artery lesions and Cox proportional hazards models using P 0.15 as both
left ventricular function. For the purposes of this analy- entry and elimination criteria were used. Other variables
sis, patients were classified by severity of CAD into eight that were candidates for inclusion in the model included
anatomic levels using a scheme that incorporates the num- age, gender, ejection fraction, previous myocardial in-
ber of stenotic vessels (that is, 70% lesion) and the farction, number of vessels diseased/proximal LAD in-
location of stenoses in the left anterior descending artery volvement, and numerous comorbid conditions.
(LAD) [11, 24]. Left ventricular ejection fraction was To best assess the influence of revascularization strat-
categorized for each patient as 20%, 20 to 29%, 30 to egy (either CABG surgery or PCI) on survival among
39%, and 40%. Within these registries, each patient’s patients stratified on degree of renal dysfunction, sur-
serum creatinine and dependence on dialysis prior to vival was modeled separately for patients in the cohorts
their revascularization procedure are captured and re- described by creatinine 2.5 mg/dL but not requiring
corded at the time of the procedure as falling into one dialysis and patients with ESRD. Treatment strategy was
of three categories: (1) creatinine2.5 mg/dL, (2) creati- coded as a binary-independent variable and was forced
nine 2.5 mg/dL but not dialysis dependent, or (3) into the models so that its level of association could be
ESRD requiring dialysis. Additionally, within these reg- ascertained. Survival was initially modeled within each
istries, patients receiving both hemodialysis and perito- stratum of renal function using patients in all of the CAD
anatomic groups. To avoid invalid statistical comparisonneal dialysis as well as patients with a functioning renal
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of survival between treatments in subgroups of patients Compared with patients with creatinine 2.5 mg/dL,
having a serum creatinine 2.5 mg/dL or ESRD was anwith unbalanced utilization (that is, among patients in
whom the choice of therapy, CABG surgery vs. PCI, independent predictor of mortality among patients in
each anatomic distribution of CAD (modeled separately;was dictated by the severity of CAD), patients in CAD
anatomic groups in which one treatment strategy was Fig. 1). These predictors were all highly significant except
among patients with creatinine 2.5 mg/dL with two-utilized less than 10% of the time were excluded from
the analysis. Exclusion of anatomic groups with this un- vessel CAD (without LAD involvement) among whom
only a similar trend was present. The mortality risk asso-balanced utilization was performed to focus the analysis
on patients who were more likely to have been eligible ciated with ESRD as compared to having a serum creati-
nine2.5 mg/dL was greater than the increment in mor-for either revascularization procedure. The interaction
between the presence of diabetes mellitus and treatment tality associated with a creatinine2.5 mg/dL compared
with the same reference group in all anatomic distribu-strategy was tested in separate models. A P value of0.10
was used as both entry and elimination criteria for these tions. Other predictors of mortality in each of the models
include left ventricular ejection fraction, presence of dia-analyses.
Cox proportional hazards regression was used to ad- betes mellitus, other comorbid conditions such as periph-
eral vascular and cerebrovascular disease, and hemody-just Kaplan–Meier survival curves for CABG surgery
and PCI where treatment was used as a stratification namic instability (data not shown).
Among ESRD patients with a balanced utilization offactor instead of a modeled covariate. Survival curves
were constructed for patients with ESRD. treatment strategies (N  182 following exclusions),
multivariable Cox regression analysis demonstrated aAll P values reported are two sided, and all confidence
intervals reported are 95% intervals. All analyses were survival benefit following CABG as compared with PCI
(RR  0.39, P  0.0006; Table 3). Other significantperformed using SAS (version 6.12; SAS Institute Inc.,
Cary, NC, USA). predictors of mortality among ESRD patients include
increasing severity of CAD, increasing age, ejection frac-
tion 30%, prior history of stroke, presence of periph-RESULTS
eral vascular disease, and persistent ventricular arrhyth-
Demographic features, clinical variables, and severity mia. The presence of diabetes mellitus did not interact
of CAD are compared between cohorts of patients strati- significantly with revascularization strategy (CABG vs.
fied on degree of renal insufficiency (Table 1). Patients PCI). Adjusted Kaplan–Meier survival curves comparing
with creatinine2.5 mg/dL were older than patients with survival following CABG surgery as compared with PCI
creatinine2.5 mg/dL and patients with ESRD. Patients among patients with ESRD are demonstrated in Figure
with either creatinine 2.5 mg/dL or ESRD had poorer 2. Survival estimates at one, two, and three years in the
left ventricular function and more severe CAD, as com- adjusted analysis were 70.8, 51.9, and 46.1%; and 84.1,
pared with patients with creatinine 2.5 mg/dL. Com- 77.4, and 65.9% for ESRD patients undergoing PCI and
paring frequency of comorbid conditions, a greater pro- CABG, respectively. Survival estimates at one, two, and
portion of patients with creatinine2.5 mg/dL or ESRD three years in the unadjusted analysis were 75.9, 58.9,
had diabetes mellitus, peripheral vascular disease, cere- and 54.0%; and 81.8, 74.7, and 62.3% for ESRD patients
brovascular disease, left ventricular hypertrophy, chronic undergoing PCI and CABG, respectively. The survival
obstructive pulmonary disease, and congestive heart fail- benefit among ESRD patients undergoing CABG was
ure as compared with patients with creatinine2.5 mg/dL. similar and confirmed among patients in all CAD ana-
Regardless of therapy, unadjusted mortality rates for tomic groups (N  407, data not shown).
patients with creatinine 2.5 mg/dL or ESRD at three Among patients with creatinine 2.5 mg/dL with a
years were much greater than for patients with creatinine balanced utilization of treatment strategies (N  378
2.5 mg/dL (24.9 and 34.6% as compared with 2.6%). following exclusions), CABG surgery was not associated
Comparing cohorts of patients by initial revasculariza- with a statistically significant mortality benefit as com-
tion strategy, patients undergoing CABG surgery had pared with PCI (RR  0.86, 95% CI, 0.56 to 1.33, P 
poorer left ventricular function, more severe CAD, and 0.50) in the multivariable model (data not shown).
greater frequency of comorbidities as compared with CABG surgery was similarly not associated with a sur-
patients undergoing PCI (Table 2). Within cohorts of pa- vival benefit in an analysis among all CAD anatomic
tients undergoing CABG and PCI, patients with ESRD groups (N  840, data not shown).
or creatinine 2.5 mg/dL had poorer left ventricular
function than patients with creatinine2.5 mg/dL (Table
DISCUSSION2). Similar, although less marked differences in severity
of CAD were seen among cohorts of patients undergoing In 1997, there were 304,000 prevalent U.S. ESRD pa-
tients [1]. This population has increased by 7% per year,CABG or PCI based on renal function (Table 2).
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Table 1. Characteristics of the study population
Creatinine 2.5 Creatinine 2.5 ESRD
N 58,329 840 407
Age years 63.1 (11.0) 67.3 (11.4) 61.1 (11.3)
Female gender 17,643 (30.3) 262 (31.2)a 143 (35.1)b
Race
White 53,050 (90.9) 706 (84.0)c 308 (75.7)c
Black 2,832 (4.9) 94 (11.2) 75 (18.4)
Other 2,447 (4.2) 40 (4.8) 24 (5.9)
Left ventricular ejection fraction
20% 517 (0.9) 25 (3.0)c 10 (2.5)c
20–29% 2,398 (4.1) 94 (11.2) 35 (8.6)
30–39% 5,638 (9.7) 187 (22.3) 50 (12.3)
40–49% 11,349 (19.5) 167 (19.9) 88 (21.6)
50% 34,161 (58.6) 270 (32.1) 180 (44.2)
Not coded 4,266 (7.3) 97 (11.5) 44 (10.8)
Coronary artery disease severityd
1 vessel, no LAD 11,612 (19.1) 66 (7.9)c 62 (15.2)c
1 vessel, non-proximal LAD 4,229 (7.3) 35 (4.2) 19 (4.7)
1 vessel, proximal LAD 7,700 (13.2) 56 (6.7) 29 (7.1)
2 vessel, no LAD 3,768 (6.5) 54 (6.4) 27 (6.6)
2 vessel, non-proximal LAD 3,075 (5.3) 47 (5.6) 28 (6.9)
2 vessel, proximal LAD 9,392 (16.1) 156 (18.6) 70 (17.2)
3 vessel, non-proximal LAD 2,551 (4.4) 65 (7.7) 28 (6.9)
3 vessel, proximal LAD 16,002 (27.4) 361 (43.0) 144 (35.4)
Presence of comorbid conditions
Myocardial infarction within 7 days 8,249 (14.1) 79 (9.4)c 22 (5.4)c
Stroke 2,093 (3.6) 76 (9.1)c 29 (7.1)c
Carotid/cerebrovascular disease 3,659 (6.3) 145 (17.3)c 46 (11.3)c
Aortoiliac disease 2,280 (3.9) 125 (14.9)c 58 (14.3)c
Femoral/popliteal disease 4,208 (7.2) 178 (21.2)c 98 (24.1)c
Hemodynamically unstable 1,028 (1.8) 36 (4.3)c 12 (3.0)c
Shock 155 (0.3) 9 (1.1)c 4 (1.0)c
EKG evidence of LVH 4,995 (8.6) 198 (23.6)c 132 (32.4)c
Persistent ventricular arrhythmia 1,303 (2.2) 26 (3.1)c 16 (3.9)c
Chronic obstructive lung disease 5,560 (9.5) 160 (19.1)c 48 (11.8)c
Congestive heart failure 5,670 (9.7) 272 (32.4)c 93 (22.9)c
Diabetes requiring medication 12,675 (21.7) 410 (48.8)c 197 (48.4)c
Mortality rate (unadjusted at 3 years) 2.6% 24.9% 34.6%
Number of patients excluded due to
Myocardial infarction 24 hours 2,969 49a 21a
Left main lesion 50% 8,805 221c 62a
Abbreviations are: ESRD, end-stage renal disease; LAD, left anterior descending artery; LVH, left ventricular hypertrophy.
Absolute number of patients are given along with their relative percentage within their cohort based on renal function [N (%)].
a P  not significant as compared with cohort with creatinine 2.5 mg/dL
b P  0.03 as compared with cohort with creatinine 2.5 mg/dL
c P  0.00001 as compared with cohort with creatinine 2.5 mg/dL
d Severity of coronary artery disease as assessed by number and anatomic locations of variables
with the greatest growth occurring among patients 65 This observational study using a large, population-based
cohort of patients is the first to demonstrate a survivalyears old [1]. While difficult to quantitate, the population
of patients with chronic renal insufficiency, defined as a benefit to patients with ESRD undergoing CABG sur-
gery as compared with PCI, while controlling for severitybaseline serum creatinine concentration 1.7 mg/dL, is
at least 3,000,000 [26, 27]. Given these large and expanding of cardiac disease, left ventricular dysfunction, and other
comorbid factors. Furthermore, opportunity exists forpopulations with exaggerated risk of death caused by
cardiovascular disease, an increased understanding of further investigation that compares treatment strategies
among patients with chronic renal insufficiency not yetthe outcomes of the management strategies for CAD is
essential. Prior studies have demonstrated a potential requiring dialysis.
The comparative survival disadvantage offered by PCIsurvival benefit for ESRD patients undergoing CABG
surgery as compared with PCI [16, 21]. These studies, may be related in part to the greater restenosis rate
following PCI that has been observed among ESRDhowever, have been limited by either their inability to
adjust for clinical variables such as severity of CAD and patients [15, 28]. While prior reports suggest that the
restenosis rate at six months among patients receivingleft ventricular function [21] or limited power to assess
the survival benefit associated with CABG surgery [16]. hemodialysis is twice that of patients with normal renal
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Fig. 1. Mortality risk ratios (RRs) for patients with creatinine 2.5
mg/dL or end-stage renal disease (ESRD) patients () as compared
with patients with creatinine 2.5 mg/dL () within each group based
on coronary artery disease (CAD) anatomy (adjusted). The effect of
renal insufficiency was modeled separately in each anatomic group.
LAD is left anterior descending artery.
function [15, 28], it is unclear whether the increased risk
of restenosis is a step function that begins during mild to
moderate renal insufficiency. Accelerated atherogenesis
among patients with renal failure as compared with pa-
tients whose renal function is normal could be explained
by an increased prevalence of hypertension or hypervo-
lemia, qualitative and quantitative lipid abnormalities,
insulin resistance, and physical inactivity in this popula-
tion [1, 29–38]. Irrespective of etiology, the incidence,
severity, and rate of progression of atherosclerotic CAD
are arguably greater among patients with ESRD [38].
While this study demonstrates a survival benefit for
patients with ESRD undergoing CABG surgery, its con-
clusions should be interpreted in the setting of certain
limitations. Albeit based on a large, population-based
cohort, selection biases for patient inclusion may affect
these results. Only patients receiving the interventions
of CABG surgery or PCI were included in the cohort.
Referral for coronary artery imaging and intervention
may be affected by the presence of renal insufficiency
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Table 3. Mortality predictors for patients with end-stage renal disease (ESRD)
(N  182) Risk ratio 95% CI -square P value
CABG surgery compared with PCI 0.39 0.22–0.67 11.7 0.0006
Coronary artery disease anatomic groupa
2 vessels diseased, including proximal LAD 2.36 1.31–4.26 8.2 0.004
3 vessels diseased, including non-proximal LAD 1.93 0.96–3.86 3.4 0.06
Ageb 1.02 1.00–1.04 3.9 0.05
Ejection fraction 30%c 2.05 1.10–3.81 5.1 0.02
Previous stroke 2.09 0.87–5.02 2.7 0.10
Femoral/popliteal disease 1.89 1.11–3.23 5.5 0.02
Persistent ventricular dysrhythmia 2.09 0.89–4.93 2.8 0.09
Abbreviations are: CABG, coronary artery bypass grafting; PCI, percutaneous coronary artery intervention; LAD, left anterior descending artery.
a Referent group are patients with either one-vessel, proximal LAD, two-vessel non-LAD, or two-vessel non-proximal LAD disease
b Compares age increased by increments of one year
c Referent group are patients with a left ventricular ejection fraction 30%
an impact on outcome. While the presence of severity
of many of these factors is fairly objective (for example,
diminished left ventricular function), the severity of
other comorbidities such as vascular disease may not be
as accurately described in this manner. Furthermore,
although this database does contain information on
CAD anatomy, it does not contain information on lesion
type (complexity, calcification, vessel size, etc.) known
to have an impact on survival. Additionally, because of
the observational nature of this study, it is limited in its
ability to assume a cause–effect relationship between
treatment and outcome. While this association would be
strengthened by the use of cardiac death as the outcome,
the association demonstrated here is similar to that seen
Fig. 2. Adjusted Kaplan–Meier survival curves comparing coronary in other observational studies [16, 20, 21].artery bypass grafting (CABG) surgery with percutaneous coronary ar-
While a small proportion of ESRD patients undergo-tery intervention (PCI) as treatment for coronary artery disease (CAD)
among patients with end-stage renal disease (ESRD). ing PCI received stents, the numbers of patients are not
large enough to demonstrate a difference in outcome as
compared with ESRD patients undergoing PCI who did
not received coronary artery stents. As the use of stentsor ESRD due to concerns such as the risk of acute renal
has been shown to diminish the restenosis rate amongfailure among patients with pre-existing renal insuffi-
patients with [47] and without [48, 49] renal insufficiency,ciency [39–43] or increased mortality following interven-
the survival benefit to CABG demonstrated here willtion among patients with ESRD [17, 44–46]. Given this
need to be re-examined in this setting.caveat, patients included in this study may not be truly
Finally, the potential impact of misclassification biasrepresentative of the entire population of patients with
through the categorical capture of information on renalconcurrent cardiac and renal disease. While these effects
function must be recognized. A considerable range inmay be minimized by the use of this population-based
calculated creatinine clearance may be represented bycohort incorporating a range of practice and referral pat-
the measure of any one value of serum creatinine dueterns, the potential impact of a bias that excludes patients
to the influence of body size and muscle mass [50]. Exactshould be recognized when generalizing these results to
creatinine measurements were not available in this datathe entire population of patients with renal insufficiency
set. Given this fact, we were not able to calculate creati-or ESRD.
nine clearance for each patient to account for this vari-Indication bias may impact the results of any observa-
ability. If the survival benefit obtained from CABG sur-tional study in that the indication for treatment may
gery is a step function that begins among patients withaffect the likelihood of the outcome. This bias may be
chronic renal insufficiency, our inability to quantitateminimized through multivariable modeling to control for
more accurately each patient’s degree of renal insuffi-factors such as severity of CAD, left ventricular dysfunc-
ciency may have resulted in our inability to demonstratetion, and the presence of comorbidities (for example,
this relationship statistically. Further investigation to as-diabetes mellitus, peripheral vascular disease), which
might influence the choice of therapy and may also have sess for a potential threshold of renal function below
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